NCT05905068View on ClinicalTrials.gov

Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 14, 2023

Primary Completion Date

February 24, 2024

Study Completion Date

May 14, 2024

Conditions
To Reduce the LDL-C Level in Hypercholesteremia Adult PatientsCombination for Subgroup High LDL-c Patients With Other Comorbidities
Interventions
DRUG

RN0191 INJECTION

a sterile solution in each bottle for subcutaneous (SC) injection

Trial Locations (1)

4006

Nucleus Networks, Herston

Sponsors
All Listed Sponsors
lead

Ikaria Bioscience Pty Ltd

INDUSTRY

NCT05905068 - Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects | Biotech Hunter | Biotech Hunter